RxDoctor Payments Data

Jerry Bell, DO

Family Medicine · Madison, OHNPI 1962626564

Payments from drug & device makers

$9,928in general payments, 2019–2025

Across 629 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Pfizer$888
  • Amgen$462
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$9,86399%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,928 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$34,165
Medicare patients
212
Services billed
556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide69$78,112
Tresiba Flextouch U-200Insulin Degludec53$71,860
EliquisApixaban63$66,195
FarxigaDapagliflozin Propanediol69$65,031
RybelsusSemaglutide35$52,375
TrulicityDulaglutide36$49,785
OzempicSemaglutide58$49,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$47,515
XareltoRivaroxaban42$42,191
Baclofen30$36,909
JardianceEmpagliflozin37$34,769
Breo ElliptaFluticasone/Vilanterol64$33,195
Tresiba Flextouch U-100Insulin Degludec50$27,497
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$21,147
MyrbetriqMirabegron27$16,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,021$127,896105 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$389$101,857163 claims
Novo NordiskRybelsus, Ozempic$1,428$101,47993 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,381$88,310127 claims
PfizerEliquis$888$66,19563 claims
Johnson & JohnsonXarelto$95$42,19142 claims
Boehringer IngelheimJardiance, Combivent Respimat$330$41,64851 claims
Astellas Pharma US IncMyrbetriq$193$16,83627 claims
AbbVieLinzess, Synthroid$1,258$13,33693 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Madison

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →